
Examining the overall health and financial system benefits of managing obesity at all ages, beginning July 1, 2026, eligible Medicare beneficiaries will have a new, lower-cost option for FDA-approved GLP-1 medications used to treat obesity. This is big news!
The new Medicare GLP-1 Bridge Program is a temporary pilot that gives qualified plan participants access to medications such as Wegovy® and Zepbound® for a $50 monthly copay through December 31, 2027. Until now, Medicare covered only GLP-1 medications prescribed for conditions such as type 2 diabetes or cardiovascular disease — not obesity alone.
Beneficiaries must be:
- Enrolled in Medicare Part D or a Medicare Advantage plan with drug coverage
- Meet specific medical criteria for obesity
- Receive prior authorization from their healthcare provider
Right now, this program operates outside of Part D formularies. However, if successful, it could help shape future Medicare policy regarding currently excluded anti-obesity medications. If you think you would benefit from a GLP-1 and might qualify for coverage, speak with your physician and a Medicare adviser like Health Directions to learn whether the program is appropriate for you.
Resources: cms.gov; kff.org; medpac.gov



